When Ginny Mason was diagnosed with inflammatory breast cancer in 1994, she never once heard the word “biomarker.” “Back then, all you got was ER and PR [the estrogen receptor and progesterone ...
As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...
An enigmatic type of circulating tumor cell called a dual-positive (DP) cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators ...
T cells are supposed to be relentless. These white blood cells patrol the body, identify threats, and destroy them.
Primary Results of ROSE/TRIO-12, a Randomized Placebo-Controlled Phase III Trial Evaluating the Addition of Ramucirumab to First-Line Docetaxel Chemotherapy in Metastatic Breast Cancer Although ...
News-Medical.Net on MSN
Dual-positive hybrid cells linked to shorter survival in advanced breast cancer
An enigmatic type of circulating tumor cell called a dual-positive (DP) cell is associated with shorter survival time in patients with advanced breast cancer, according to a study led by investigators ...
Researchers at Moffitt Cancer Center have identified distinct spatial tumor–immune ecosystems that predict whether patients with advanced non–small-cell lung cancer will benefit from immunotherapy.
Research shows tumor debulking in advanced colorectal cancer does not enhance survival outcomes and may increase adverse effects, questioning its efficacy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results